Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Biologic to Start Trial of New Plasma Product

publication date: Sep 17, 2008

China Biologic Products, Inc. received permission from the SFDA to begin a clinical trial of its new Human Coagulation Factor VIII product (FVIII), a coagulation treatment for hemophilia and mass hemorrhaging. China Biologic focuses on plasma-based products. Because plasma has been in short supply in China, prices for all plasma-based products have been high, and China Biologic’s financial fortunes have risen. More details...

Stock Symbol: (OTCBB: CBPO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital